JPRN-jRCT2080221367未知2 期
A phase II open label randomized multicenter trial of TSU-68 in combination with docetaxel versus docetaxel alone in patients with metastatic breast cancer previously treated with an anthracycline.
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- Female
入选标准
- •(1) Signed, written informed consent.
- •(2) Eastern Cooperative Oncology Group (ECOG) performance status of =< 2.
- •(3) Non-pregnant, non-breastfeeding.
排除标准
- •(1) Symptomatic brain metastasis or inflammatory breast cancer.
- •(2) Any significant disease that, by the Investigator's opinion, should exclude the patient from the study.
- •(3) History of drug abuse within 6 months prior to the start of study treatment
研究者
相似试验
未知
2 期
A phase II study of TSU-68 in patient with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080221366Taiho Pharmaceutical Co., Ltd.100
进行中（未招募）
不适用
Phase II open-label randomized multicenter trial to compare the efficacy and safety of two different doses of raltegravir and efavirenz, all in combination with tenofovir and lamivudine, in naive HIV-1-infected patients receiving rifampin for active tuberculosis. - REFLATE TBHIV-1 Infection and tuberculosisMedDRA version: 11.0Level: LLTClassification code 10020161Term: <Manually entered code. Term in E.1.1>EUCTR2008-004970-41-FRAgence nationale de recherches sur le sida et les hépatites virales. ANRS.150
招募中
不适用
Clinical trial comparing Olaparib versus standard therapy in patients with gBRCAmut-associated HR(+)/HER2(-) breast cancerKCT0006750Korea University Anam Hospital66
进行中（未招募）
1 期
Randomized open label multicentric phase II trial of Adjuvant RadioChemotherapy, Concurrent versus Sequential, in resected non-small cell lung cancer (NSCLC) patients with mediastinal involvement (pN2). The ARCCS trial.non small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10062042Term: Lung neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000364-24-ITAZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA100
进行中（未招募）
1 期
A study to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal canceradvanced esophageal squamous cell cancerMedDRA version: 20.1Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10055102Term: Oesophageal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10030151Term: Oesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10015363Term: Esophageal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10030152Term: Oesophageal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10062478Term: Esophageal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002056-86-DEAIO-Studien-gGmbH75